Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm
Article 2025 en
Authors
MK
Monika Kozieł-Siołkowska
ES
Eduard Shantsila
AS
Alena Shantsila
Abstract
1 min read
There is some evidence from RCTs that OAC with warfarin compared to platelet inhibition with aspirin probably has little to no effect on mortality in people with systolic heart failure in sinus rhythm (moderate-certainty evidence). Treatment with warfarin probably reduces non-fatal cardiovascular events but probably increases the risk of major bleeding complications (moderate-certainty evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (low-certainty evidence). At present, there are no data on the role of OAC versus antiplatelet agents in heart failure with preserved ejection fraction in sinus rhythm. Also, there were no data from RCTs on the utility of non-vitamin K antagonist oral anticoagulants compared to antiplatelet agents in heart failure with sinus rhythm.
Deirdre A. Lane, Nikolaos Dagres, Gheorghe‐Andrei Dan, Javier García Seara, Konstantinos Iliodromitis, Radosław Lenarczyk, Professor Gregory Lip, Jacques Mansourati, Francisco Marı́n, Douglas S. Scherr, Tatjana Potpara
Siqin Ye, Min Qian, Bo Zhao, Richard Buchsbaum, Ralph L. Sacco, Bruce Levin, Marco R. Di Tullio, Douglas L. Mann, Patrick M. Pullicino, Ronald S. Freudenberger, John R. Teerlink, J.P. Mohr, Susan Graham, Arthur J. Labovitz, Conrado J. Estol, Dirk J. Lok, Piotr Ponikowski, Stefan D. Anker, Professor Gregory Lip, John L.P. Thompson, Shunichi Homma
Discussion(0)
No comments yet. Be the first to comment.